Wowing a Study Section

The article "How To Wow A Study Section: A Grantsmanship Lesson" by Karen Hopkin in the March 2 issue of The Scientist (12[5]:11) contains a lot of good advice about writing grant applications. However, it also has a few errors that might mislead researchers not familiar with the National Institutes of Health application and review process. Hopkin writes about the study section meeting: "the reviewer who gave your proposal the highest relative score presents your application." It is my underst

Written byLiane Reif-lehrer
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Hopkin writes about the study section meeting: "the reviewer who gave your proposal the highest relative score presents your application." It is my understanding that two or three primary reviewers each present their reports. Scores are assigned by secret ballot after the general discussion (but before the budget discussion).

Hopkin writes there are "usually three" primary reviewers. I am under the impression that there are most commonly two (although there may, on occasion, be a third) but there are now also one or two (and sometimes apparently more) "readers" who also comment on the proposal.

Hopkin quotes one source, "use at least a 12-point font...or you may find that your application is returned for reformatting." Although a 12-point font would be kind to reviewers--as long as you follow the NIH instructions about type size (page 6 of PHS 398, Rev. 5/95, reprinted 6/96), NIH would have no grounds to return ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies